Chemical design of inhibitors of ERK1/2 dephosphorylation

  • 59 Pages
  • 4.17 MB
  • English
Laurentian University , Sudbury, Ont
Statementby Alicia Bacanovic.
The Physical Object
Paginationviii, 59 l. :
ID Numbers
Open LibraryOL22179258M

Download Chemical design of inhibitors of ERK1/2 dephosphorylation PDF

ERK1/2 has a low propensity for the “DFG-out” conformation due to the presence of residues in the catalytic domain that stabilize the “DFG-in” state Indeed, ERK1/2 co-crystal structures exclusively revealed type I binding modes 15 and to date VTXe remains the only available potent, type-I ERK1/2 inhibitor 4,13,Interestingly, the highly potent and selective ERK1/2 inhibitor Cited by:   In contrast, dual mechanism ERK1/2 inhibitors could disrupt the phosphorylation of ERK1/2, and reduce the nuclear translocation ERK1/2, resulting in a pool of inhibitor-bound ERK1/2 in the cytoplasm.

Alternatively, this nuclear p-ERK1/2 pool induced by catalytic ERKi treatment could potentially play a role in maintaining the non-catalytic Cited by: The p38 MAP Kinase Inhibitor VIII, also referenced under CAScontrols the biological activity of p38 MAP Kinase.

This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Sigma-Aldrich. ERK1/2 are proline-directed kinases that preferentially catalyze the phosphorylation of substrates containing a PxS/TP sequence.

The dephosphorylation and inactivation of ERK1/2 is catalyzed by dual specificity phosphatases, protein-tyrosine specific phosphatases, and protein-serine/threonine by: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed.

Optimization led to the identification of (S)- 14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft by: It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation.

S Ravoxertinib (GDC) GDC is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of nM and nM, respectively.

Phase 1. Nat. Since CacyBP/SIP binds ERK1/2 and inhibits its activity, in this work we tried to establish whether CacyBP/SIP has phosphatase activity toward ERK1/2 kinases. At first we verified the phosphatase activity of CacyBP/SIP toward a standard substrate, p -NPP and calculated the K m and V max values as well as IC 50 for the phosphatase inhibitor.

Previously, we showed that mAChRs promote global protein biosynthesis via both the MEK1/2-ERK1/2 and mTORC1-S6K1 pathways in SNU cells [].To determine whether these signaling pathways are involved in mAChR-mediated eEF2 dephosphorylation, we used the MEK1/2 inhibitor U and the mTORC1 inhibitor rapamycin.

In contrast to p, p dephosphorylation is a late event that we had defined as a characteristic of the “maintenance” of growth arrest and probably results from inactivation of cyclin-dependent kinases. p dephosphorylation is partially blocked by both types of inhibitors. ERK1/2 and p38 MAPK can regulate the expression and the.

The Ras/Raf/MEK/ERK signal transduction, an oncogenic pathway implicated in a variety of human cancers, is a key target in anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change for Chemical design of inhibitors of ERK1/2 dephosphorylation book compound 2, when bound to ERK2 relative to antitarget GSK3, enabled structure-guided selectivity optimization.

The described binding mode of SCH with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity. Discover the world's research 17+ million members. The described binding mode of SCH with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.

Access through your institution Buy or subscribe. Heterobifunctional molecules have proven powerful tools to induce ligase-dependent ubiquitination of target proteins.

We describe here a chemical strategy for controlling a different post-translational modification (PTM): phosphorylation.

Heterobifunctional molecules were designed to promote the proximity of a protein phosphatase (PP1) to protein targets. The.

In addition, PPARγ can be phosphorylated by ERK1/2, and dephosphorylation of PPARγ by ERK1/2 inhibitors enhances PPARγ transcriptional activity (23–28). In this study, we investigated the effect of PPARγ activation by ligands or dephosphorylation with ERK1/2 inhibitors on hepatic PCSK9 expression both in vitro and in vivo.

NSC was the first identified SHP2 PTP inhibitor via screening the National Cancer Institute (NCI) diversity set chemical library in (Fig. 4A). It potently inhibited SHP2 (IC 50 = μM) and exhibited high selectivity for SHP2 over other PTPs (PTP1B, DEP1, HePTP, LAR, CD45) but no selectivity among SHP2 and SHP1 was observed.

Panel B: ERK1/2 in liver and spleen tissue extracts Panel C: The degree of inhibition for protein, acid and alkaline phosphatase activity was determined in mouse brain extract after treatment with Pierce Phosphatase Inhibitor Tablets or another commercially available phosphatase inhibitor tablet.

Percent inhibition is indicated. The hematopoietic protein tyrosine phosphatase (HePTP) is implicated in the development of blood cancers through its ability to negatively regulate the mitogen-activated protein kinases (MAPKs) ERK1/2 and p Small-molecule modulators of HePTP activity may become valuable in treating hematopoietic malignancies such as T cell acute lymphoblastic leukemia (T-ALL) and.

Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion. Nutrition. Here, we report the development of a non-covalent clickable probe, based on SCH, a slow off-rate ERK1/2 inhibitor, which enabled efficient pull down of ERK1/2 protein via click reaction with tetrazine tagged agarose beads.

This was used in a competition setting to measure relative target occupancy by selected ERK1/2 inhibitors. There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications.

Description Chemical design of inhibitors of ERK1/2 dephosphorylation PDF

The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2. PHPS1 also blocks Shp2-dependent downstream signaling, namely HGF/SF-induced sustained phosphorylation of the Erk1/2 MAP kinases and dephosphorylation of paxillin.

Furthermore, PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-associated Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of. The kinetics of Erk1/2 dephosphorylation in the absence (Fig.

9A) or in the presence (Fig. 10B) of NAC would then be indicative of Erk1/2-directed phosphatase activity. As shown in Figure 10B, the post-TPA-treatment with NAC stimulated a marked and rapid dephosphorylation of Erk1/2 within minutes of treatment with NAC, presumably in response.

Proper cellular responses to growth factors, cytokines, and various forms of environmental stress are carried out by a network of complex and diverse signal transduction pathways, which usually involve mitogen-activated protein (MAP) 1 kinase(s). The three best characterized MAP kinases are the extracellular signal-regulated kinase (ERK), the c-Jun N-terminal kinase (JNK), and the.

The rapid inactivation of the ERK1/2 pathway will result in dephosphorylation and substantial stabilization of pre-existing and newly synthesized Bim EL, which will be accompanied by increases in Bim mRNA because of activation of JNK or loss of PI3K or ERK1/2 activity, depending on the cell type.

Often, SCH treatment suppresses dual phosphorylation of ERK1/2, while Vertexe increases phosphorylation, without affecting the activity state of MKK1/2.

Details Chemical design of inhibitors of ERK1/2 dephosphorylation PDF

Therefore, we investigated whether these inhibitors could affect dephosphorylation of 2P-ERK2 catalyzed by the MAP kinase phosphatase MKP3/DUSP6. ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of nM against ERK1 and ERK2, respectively.

- Mechanism of. Sulindac resulted in inhibition of phospho-ERK1/2 expression by 12 h of drug treatment that persisted through 72 h (Figs. 3B ⇓ and 4A and B) ⇓, without decreased expression of total ERK1/2 protein, except for total ERK1 at 72 h after treatment (Figs.

3B ⇓ and 4 ⇓, C and D). The phosphorylation state of ERK1/2 is balanced by both activator of ERK1/2 kinase and activator of ERK1/2 phosphatase. DUSP is a dual-specificity protein phosphatase. DUSP6 is specifically responsible for ERK1/2 dephosphorylation (1, 26).

Our present study showed that aldosterone enhanced NCC protein expression along with increasing DUSP6. Recent clinical and therapeutic success with RAF and MEK1/2 inhibitors has revolutionized the existing treatment schemes for previously incurable cancers like melanomas.

However, the overall therapeutic efficacies are still largely compromised by the dose-limiting side effects and emerging drug resistance mechanisms. Accumulating evidence has revealed the intricate nature of the. Binding of ERK1/2 to the KIM of PTP-SL blocks the nuclear translocation of these MAP kinases, and favors their dephosphorylation and inactivation by the phosphatase in the cytoplasm (Zúñiga et al.

Essential residues within the KIM of PTP-SL for the recognition of ERK1/2 include those within a PKA consensus phosphorylation sequence. Protein phosphatase 2A (PP2A) 1 is a family of mammalian serine/threonine phosphatases that accounts for the major portion of serine/threonine kinase activity in most cells.

PP2A is a trimeric holoenzyme complex and is composed of a catalytic C subunit, a structural A subunit, and a regulatory B-type subunit, each encoded by separate genes (1, 2).

The fact that the MEK‐Erk1/2 inhibitor U precluded both GSK3 activation and tau phosphorylation indicates that this event is initially triggered by MEK‐Erk1/2.

On the other hand, the kinetic data and the prevention of tau phosphorylation by a specific inhibitor of GSK3 suggest that this kinase is directly responsible.transcription factors. ERK1/2 are proline-directed kinases that preferentially catalyze the phos-of substrates containing a Pro-Xxx-Ser/Thr-Pro sequence.

Besides this primary structure requirement, many ERK1/2 substrates possess a D-docking .